References
BMC Medical Genomics. 2015. volume 8, Article number 45.
Journal for ImmunoTherapy of Cancer 2022;10:e003826.
 

--- 

Support this podcast: <a href="https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support" rel="payment">https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support</a>

ImmunoEpigenetics59. The P53/AKT/PHLDA3 axis over tumorigenicity is controlled by endomembraneous targeting via glycerol lipid PhosphatidylInositol bis-phosphate (PIP2) phosphorylation to PIP3.5.12.23

Become a Paid Subscriber: https://anchor.fm/dr-daniel-j-guerra/subscribe


Become a Paid Subscriber: https://anchor.fm/dr-daniel-j-guerra/subscribe

You have wisely landed upon Authentic Biochemistry, with Dr. Daniel J Guerra, where published biochemical, physiological, genetic and immunological research along with biomedical and pharmaceutical science are interrogated.

Anchor (from Spotify)

Authentic Biochemistry

ImmunoEpigenetics 57. Plasmacytoid dendritic cell neoplasias and the CAR-T cell tumor microenvironment exposure altering epigenetic TF regulation leading to diverse differentiation. DJGPhD.20.4.23

ImmunoEpigenetics 58. Epigenetic mechanisms role in Loss of Heterozygosity (LOH) in TSG's advancing targeting of solid tumors via pharmacotherapeutic CAR-T cells. DJGPhD 27.4.23. Authentic Biochem.